TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...
Richmond, Virginia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today ...
(Reuters) -Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump ...
Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...
Cellares and Cabaletta Bio announced Wednesday the successful completion of the manufacturing Technology Adoption Program (TAP) using the Cell Shuttle platform. NJBIZ has reported extensively about ...
Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...
A straZeneca plans to invest $50 billion in its medicine manufacturing and R&D operations across the United States by 2030. The investment is expected to create tens of thousands of new, highly ...
Hosted on MSN
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S. U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results